Novonesis A S (NVZMF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the NovoNezis conference call regarding the first half 2025 financial result as well as the 2030 growth strategy. My name is Yousef, the course call operator. I would like to remind you that all participants will be in listen-only mode and that this conference will be recorded. The presentations will be followed by a Q&A session. You can register for questions at any time by pressing star followed by one on your telephone. For operator assistance... This conference must not be recorded for publication or for broadcast. At this time, it's my pleasure to hand over to Tobias Cornelius Bjoklund. Please go ahead. Thank you, Operator, and welcome everyone to the Novenesis conference call, both for the first half of 2025 and also including the presentation of the 2030 Strategy and Financial Targets. In this call, our CEO, Esther Baggett, and our CFO, Reiner Lehmann, will review our performance for the first half of the year, as well as the outlook for 2025. Attending today's call, we have the full executive leadership team, Henrik Jörg Nilsson, EVP of Human Health Biosolutions, Andrew Taylor, EVP of Food and Health Biosolutions, Tina Feiner, EVP of Planetary Health Biosolutions, Klaus-Krone Fuglsang, Chief Scientific Officer, Anders Lund, Chief Operating Officer, and Mårten Rasmusson, EVP of People and Stakeholder Relations. The conference call lasts for about one hour and 40 minutes. We will start by going through the performance for the first half of 2025, and then our full executive leadership team will take you through our 2030 growth strategy. The presentation will last for approximately one hour, and we will then open up for Q&A after the full presentation. Now, please change to the next slide. As usual, I would like ...